Preclinical studies with therapeutic Src inhibitors (dasatinib, saracatinib, and bosutinib) demonstrated anti-tumor and anti-osteoclast effects, as well as clinical studies provided evidence that Src-family kinase inhibitors might be beneficial for patients with refractory disease (Boyce and Xing, 2011). Here, SRC is linked to neoplasm.